Xynomic Pharmaceuticals

Private

ShanghaiHealthcare & Life Scienceshttp://xynomicpharma.com/en/506-11/

Last Round

M&A

May 15, 2019

Est. Valuation

$350M

Total Funding Raised

$26.5M

Company Overview

Xynomic Pharmaceuticals is a biopharmaceutical company that focuses on in-licensing, developing, and commercializing oncology drug candidates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncology therapeuticsbiopharmaceuticalclinical-stage biotechbiotechHDAC inhibitordrug developmentpharmasmall-molecule drugsclinical trialsmTORC1/2 inhibitorin-licensingcancer researchdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xynomic Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

Xynomic Pharmaceuticals comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Xynomic Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
M&A	May 15, 2019
Series B	Aug 1, 2018
Debt	May 1, 2018
Debt	Apr 1, 2018
Debt	Aug 15, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Mark Xu

Chairman, CEO & President

Executive Team

Xynomic Pharmaceuticals Investors

Notable investors and investment history

Xynomic Pharmaceuticals investors
Investor	Rounds
Northern Light Venture Capital	Series B
Jingxu Venture Capital	Series A, Series B

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 1, 2018
$1.4M debt round completed.

View all signals

Xynomic Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Xynomic Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xynomic Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai

Employee Range13

Year Founded2016

Last FundingMay 15, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.